Department of Haematology, University Hospital.
Br J Haematol. 2010 Jan;148(1):110-4. doi: 10.1111/j.1365-2141.2009.07929.x. Epub 2009 Oct 11.
The present study explored the impact of two novel criteria; having >95% abnormal plasma cells by flow cytometry at diagnosis and the evolving subtype of the disease, as predictors of progression in 61 smouldering multiple myeloma (SMM) and 311 monoclonal gammopathy of unknown significance (MGUS) patients. Although both criteria were of prognostic value, the risk of progression was better identified by immunophenotyping [Hazard Ratio (HR) 6.2 and 17.2 for SMM and MGUS, respectively] than evolving subtype, which had independent prognostic value only in MGUS (HR 3.6). Immunophenotyping discriminated the different risk of progression within the evolving and non-evolving subgroups of SMM (P = 0.01) and MGUS (P < 0.001).
本研究探讨了两个新的标准，即在诊断时通过流式细胞术有＞95%的异常浆细胞和疾病的不断发展的亚型，作为 61 例冒烟型多发性骨髓瘤（SMM）和 311 例意义未明的单克隆丙种球蛋白血症（MGUS）患者进展的预测因子。虽然这两个标准都具有预后价值，但免疫表型分析（SMM 和 MGUS 的危险比分别为 6.2 和 17.2）比疾病的不断发展的亚型更好地识别了进展的风险，后者仅在 MGUS 中具有独立的预后价值（危险比 3.6）。免疫表型分析在不断发展和非发展的 SMM 亚组（P = 0.01）和 MGUS 亚组（P < 0.001）中区分了不同的进展风险。
